Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Learn about the burden of influenza, guideline updates for treatment, timing of antiviral initiation and more.
Choose from the criteria below to find an activity that fits you best.
View the other Modules in this CSPE Core Curriculum Series:
Hepatitis C Module #1: The abCs of HCV
Hepatitis C Module #3: HCV Drug Therapy Management
Hepatitis C Module #4: Treatment of HCV in Special Populations, HCV Resistance, and the Future of HCV Therapy
|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
Hepatitis C virus (HCV) has become one of the most common infections worldwide. According to the CDC, up to 3.9 million people in the United States may be infected. Healthcare costs associated with this disease have been climbing steadily to make it one of the costliest diseases to treat. Individuals infected with this contagious virus can remain asymptomatic for many years until HCV manifests into a serious clinical presentation. The disease can be acute or chronic ranging from mild to life threating in severity. This comprehensive four module program will provide a complete overview of HCV including disease state info, treatments, therapy selection, monitoring, and future considerations. Module Two will discuss the evolution of HCV treatments and the pharmacology of current agents. Possible drug interactions will also be reviewed.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
Jason J. Schafer, PharmD, MPH, BCIDP, AAHIVP
Professor, Department of Pharmacy Practice
The Jefferson College of Pharmacy
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Jason Schafer has served as an advisory board member for Merck and as a primary investigator for Gilead and Merck.
Release Date: 04-03-2020
Expiration Date: 04-03-2023
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-209-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.